Showing results (41-50 of 152) with videos related to

Sort By:
Pageof 16
European Journal of Clinical Pharmacology|October 21, 2018
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairmentMatthew P Kosloski, Haoyu Wang, David Pugatch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 6, 2019
Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported OutcomesZobair M Younossi, Maria Stepanova, Ira Jacobson, et al.
Antiviral Therapy|October 25, 2017
Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitorEric Lawitz, Jenny C Yang, Luisa M Stamm, et al.
Antiviral Therapy|December 14, 2011
Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patientsKeyur Patel, Seng G Lim, Chow W Cheng, et al.
Leukemia & Lymphoma|June 9, 2016
Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairmentJan de Jong, Donna Skee, Peter Hellemans, et al.
Hepatology (Baltimore, Md.)|October 18, 2014
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosisEric Lawitz, Fred Poordad, Diana M Brainard, et al.
Patient Preference and Adherence|December 14, 2011
Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector devicePeter Varunok, Eric Lawitz, Kimberly L Beavers, et al.
Lancet (London, England)|November 12, 2013
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialEric Lawitz, Fred F Poordad, Phillip S Pang, et al.
Virology Journal|January 31, 2018
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infectionFabien Zoulim, Christophe Moreno, Samuel S Lee, et al.
Health Science Reports|April 10, 2020
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT studyEric Lawitz, Fred Poordad, Julio A Gutierrez, et al.
Pageof 16